The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis

Trial Profile

The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2016

At a glance

  • Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms dPEP
  • Most Recent Events

    • 25 May 2016 Status changed from active, no longer recruiting to completed.
    • 16 Nov 2015 Planned End Date changed from 1 Jun 2016 to 1 Feb 2016, as per ClinicalTrials.gov record.
    • 16 Nov 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Nov 2015, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top